Cargando…

When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per...

Descripción completa

Detalles Bibliográficos
Autores principales: Marigliano, Benedetta, Rosa, Federico, Internullo, Mattia, Scuro, Luigi, Tavanti, Andrea, Del Vecchio, Lucia Rita, Romagno, Francesco Paolo, Schito, Maria Barbara, Pace, Federica, Colombo, Giovanni Maria, Guglielmelli, Emanuele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426962/
https://www.ncbi.nlm.nih.gov/pubmed/36051169
http://dx.doi.org/10.12890/2022_003451
_version_ 1784778796845498368
author Marigliano, Benedetta
Rosa, Federico
Internullo, Mattia
Scuro, Luigi
Tavanti, Andrea
Del Vecchio, Lucia Rita
Romagno, Francesco Paolo
Schito, Maria Barbara
Pace, Federica
Colombo, Giovanni Maria
Guglielmelli, Emanuele
author_facet Marigliano, Benedetta
Rosa, Federico
Internullo, Mattia
Scuro, Luigi
Tavanti, Andrea
Del Vecchio, Lucia Rita
Romagno, Francesco Paolo
Schito, Maria Barbara
Pace, Federica
Colombo, Giovanni Maria
Guglielmelli, Emanuele
author_sort Marigliano, Benedetta
collection PubMed
description Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per 100,000 population and a mortality rate of 2–10%. We describe the first case of DRESS induced by certolizumab, a biologic disease-modifying antirheumatic drug (bioDMARD). LEARNING POINTS: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome. Its recognition is critical for treatment, especially in the emergency setting where most patients first present. In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug.
format Online
Article
Text
id pubmed-9426962
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SMC Media Srl
record_format MEDLINE/PubMed
spelling pubmed-94269622022-08-31 When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy Marigliano, Benedetta Rosa, Federico Internullo, Mattia Scuro, Luigi Tavanti, Andrea Del Vecchio, Lucia Rita Romagno, Francesco Paolo Schito, Maria Barbara Pace, Federica Colombo, Giovanni Maria Guglielmelli, Emanuele Eur J Case Rep Intern Med Articles Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per 100,000 population and a mortality rate of 2–10%. We describe the first case of DRESS induced by certolizumab, a biologic disease-modifying antirheumatic drug (bioDMARD). LEARNING POINTS: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome. Its recognition is critical for treatment, especially in the emergency setting where most patients first present. In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug. SMC Media Srl 2022-07-14 /pmc/articles/PMC9426962/ /pubmed/36051169 http://dx.doi.org/10.12890/2022_003451 Text en © EFIM 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Commons Attribution Non-Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Articles
Marigliano, Benedetta
Rosa, Federico
Internullo, Mattia
Scuro, Luigi
Tavanti, Andrea
Del Vecchio, Lucia Rita
Romagno, Francesco Paolo
Schito, Maria Barbara
Pace, Federica
Colombo, Giovanni Maria
Guglielmelli, Emanuele
When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title_full When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title_fullStr When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title_full_unstemmed When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title_short When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
title_sort when autoimmunity ‘dresses up’: a case after certolizumab therapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426962/
https://www.ncbi.nlm.nih.gov/pubmed/36051169
http://dx.doi.org/10.12890/2022_003451
work_keys_str_mv AT mariglianobenedetta whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT rosafederico whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT internullomattia whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT scuroluigi whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT tavantiandrea whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT delvecchioluciarita whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT romagnofrancescopaolo whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT schitomariabarbara whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT pacefederica whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT colombogiovannimaria whenautoimmunitydressesupacaseaftercertolizumabtherapy
AT guglielmelliemanuele whenautoimmunitydressesupacaseaftercertolizumabtherapy